Management of Resolved Hepatitis B Infection with Inadequate Protective Immunity

1. Clinical Significance of Low Anti‑HBs Titers

• Patients with a resolved HBV infection but anti‑HBs < 10 IU/L lack protective immunity and are susceptible to reinfection after new exposure. 1
• Anti‑HBs < 10 IU/L signifies loss of immunity or an inadequate immune response, warranting vaccination and close monitoring when immunosuppression is contemplated. 1

2. Vaccination Recommendations

• Administer a full hepatitis B vaccine series (3 dose schedule at 0, 1, and 6 months) to achieve protective anti‑HBs levels. 1
• Measure anti‑HBs 1–2 months after the series; if the titre remains < 10 IU/L, repeat a second complete vaccine series. 1
• The target post‑vaccination anti‑HBs level is ≥ 10 IU/L for confirmed protective immunity. 1

3. Baseline HBV DNA Assessment

• Obtain baseline HBV DNA in all HBsAg‑negative, anti‑HBc‑positive individuals to detect occult HBV infection before any immunosuppressive therapy. 1, 2
• Detectable HBV DNA in this setting indicates occult infection and should prompt specialist consultation. 1

4. Risk Stratification for HBV Reactivation (2025 AGA Guideline)

High‑Risk (≥10 % reactivation)

• Regimens: anti‑CD20 antibodies, CAR‑T cell therapy, hematopoietic stem‑cell transplantation, high‑dose corticosteroids (≥20 mg prednisone‑equivalent daily for ≥4 weeks). 2
• Management: Start antiviral prophylaxis with entecavir or tenofovir before immunosuppression and continue for ≥12 months after B‑cell‑depleting agents (or ≥6 months after other high‑risk therapies). 2

Moderate‑Risk (1–10 % reactivation)

• Regimens: anti‑TNF agents, corticosteroids ≥4 weeks at moderate/high dose, anthracyclines, tyrosine‑kinase inhibitors. 2
• Management Options:
  
  • Prefer antiviral prophylaxis; if monitoring is chosen, perform HBsAg and ALT testing every 1–3 months together with HBV DNA quantification. 2, 3

Low‑Risk (<1 % reactivation)

• Regimens: short‑course corticosteroids (<1 week) or low‑dose, intra‑articular steroid injections. 2
• Management: Monitoring alone is acceptable. 2

5. Antiviral Prophylaxis Choice

• Entecavir or tenofovir are strongly preferred for prophylaxis because of their high barrier to resistance; lamivudine is discouraged. 2

6. Duration of Prophylaxis and Risks of Early Discontinuation

• For B‑cell‑depleting therapies, prophylaxis must extend at least 12 months after the last dose to cover prolonged B‑cell depletion. 2
• Premature cessation can lead to late HBV reactivation, with up to a 40 % cumulative 2‑year risk in transplant recipients. 2, 4

7. Monitoring Strategies When Prophylaxis Is Not Used

• In anti‑TNF‑treated patients, reactivation risk is low (0.8–2.5 %); nevertheless, HBV DNA should be checked every 3 months if prophylaxis is omitted. 2

8. Common Clinical Pitfalls (and How to Avoid Them)

• Mistake: Assuming anti‑HBc positivity alone confers immunity. Correction: Protective immunity requires anti‑HBs ≥ 10 IU/L. 1
• Mistake: Omitting baseline HBV DNA testing before immunosuppression. Correction: Perform HBV DNA assessment in all HBsAg‑negative, anti‑HBc‑positive patients. 1, 2
• Mistake: Using lamivudine for prophylaxis. Correction: Choose entecavir or tenofovir due to superior resistance profiles. 2

9. Special Population Insight – Low‑Level Anti‑HBs (≈7 IU/L)

• Such low titres often reflect waning immunity from remote natural infection; vaccination can boost immunity in roughly one‑third of these individuals. 1
• Post‑vaccination anti‑HBs testing is essential to verify achievement of protective levels. 1

Interpretation of Hepatitis B Surface Antigen Non-reactive & Reactive Hepatitis B Core Antibody

Serologic Pattern Interpretation

• A non-reactive hepatitis B surface antigen (HBsAg) with a reactive hepatitis B core antibody (anti-HBc) most likely indicates resolved past hepatitis B virus (HBV) infection with natural immunity, according to the Clinical Infectious Diseases and Journal of the National Comprehensive Cancer Network guidelines 5, 6
• This serologic pattern (HBsAg negative, anti-HBc positive) typically indicates previous exposure to HBV that has resolved, with clearance of the virus from the bloodstream, as stated by the Clinical Infectious Diseases guideline 5
• The hepatitis B core antibody appears during acute HBV infection and remains detectable for life, indicating acute, recent, or previous HBV infection, as noted by the Clinical Infectious Diseases guideline 5
• To complete the interpretation, testing for hepatitis B surface antibody (anti-HBs) is recommended to determine immunity status, as recommended by the Journal of the National Comprehensive Cancer Network guideline 6, 7

Clinical Significance

• This pattern suggests the patient has recovered from a previous HBV infection and is not currently infectious, according to the Journal of the National Comprehensive Cancer Network guideline 6
• Individuals with this serologic pattern are generally not at risk for developing chronic HBV infection, as stated by the MMWR Recommendations and Reports and Clinical Infectious Diseases guidelines 5, 8
• However, these individuals may be at risk for HBV reactivation if they become immunosuppressed, particularly with certain treatments like anti-CD20/CD52 monoclonal antibodies or high-dose corticosteroids, as noted by the Journal of the National Comprehensive Cancer Network guideline 6, 7

Risk of HBV Reactivation

• Patients who are HBsAg negative but anti-HBc positive have a 3-45% risk of HBV reactivation when receiving immunosuppressive therapy, as reported by the Journal of the National Comprehensive Cancer Network guideline 6, 7
• The risk varies based on virological profile, type of immunosuppressive regimen, and underlying disease, as stated by the Journal of the National Comprehensive Cancer Network and Clinical and Molecular Hepatology guidelines 6, 7, 9
• Serum HBV DNA testing before starting immunosuppressive therapy helps define reactivation risk, as recommended by the Journal of the National Comprehensive Cancer Network guideline 7

Management Considerations

• For immunocompetent individuals without plans for immunosuppression, no specific treatment is typically needed, as stated by the Clinical Infectious Diseases guideline 5
• For patients requiring immunosuppressive therapy, HBV DNA testing is recommended before starting therapy, and antiviral prophylaxis may be considered if viremic, as recommended by the Journal of the National Comprehensive Cancer Network and Clinical and Molecular Hepatology guidelines 6, 7, 9
• Monitoring of liver function tests is recommended during immunosuppressive therapy, as stated by the Journal of the National Comprehensive Cancer Network guideline 6